Evidence map›Paper›PMID 25386651›Full record

ArticlePloS one2014

Modulating the structure of EGFR with UV light: new possibilities in cancer therapy.

Manuel Correia, Viruthachalam Thiagarajan, Isabel Coutinho, Gnana Prakash Gajula, Steffen B Petersen, Maria Teresa Neves-Petersen

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 4 countries.

Manuel CorreiaDepartment of Physics and Nanotechnology, Aalborg University, Aalborg, Denmark.
Viruthachalam ThiagarajanBioPhotonics Group, Department of Nanomedicine, International Iberian Nanotechnology Laboratory (INL), Braga, Portugal; School of Chemistry, Bharathidasan University, Tiruchirappalli, India.
Isabel CoutinhoBioPhotonics Group, Department of Nanomedicine, International Iberian Nanotechnology Laboratory (INL), Braga, Portugal.
Gnana Prakash GajulaBioPhotonics Group, Department of Nanomedicine, International Iberian Nanotechnology Laboratory (INL), Braga, Portugal.
Steffen B PetersenDepartment of Health Science and Technology, Aalborg University, Aalborg, Denmark; The Institute for Lasers, Photonics and Biophotonics, University at Buffalo, The State University of New York, New York, United States of America.
Maria Teresa Neves-PetersenBioPhotonics Group, Department of Nanomedicine, International Iberian Nanotechnology Laboratory (INL), Braga, Portugal. 2. BioPhotonics Group, Department of Nanomedicine, International Iberian Nanotechnology Laboratory (INL), Braga, Portugal and 6 Department of Clinical Medicine, Aalborg University, Søndre Skovvej 15, 9000 Aalborg, Denmark.
International Iberian Nanotechnology Laboratory · PTAalborg University · DKBharathidasan University · INUniversity at Buffalo, State University of New York · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptor tyrosine kinases. EGFR is activated upon binding to e.g. epidermal growth factor (EGF), leading to cell survival, proliferation and migration. EGFR overactivation is associated with tumor progression. We have previously shown that low dose UVB illumination of cancer cells overexpressing EGFR prior to adding EGF halted the EGFR signaling pathway. We here show that UVB illumination of the extracellular domain of EGFR (sEGFR) induces protein conformational changes, disulphide bridge breakage and formation of tryptophan and tyrosine photoproducts such as dityrosine, N-formylkynurenine and kynurenine. Fluorescence spectroscopy, circular dichroism and thermal studies confirm the occurrence of conformational changes. An immunoassay has confirmed that UVB light induces structural changes in the EGF binding site. A monoclonal antibody which competes with EGF for binding sEGFR was used. We report clear evidence that UVB light induces structural changes in EGFR that impairs the correct binding of an EGFR specific antibody that competes with EGF for binding EGFR, confirming that the 3D structure of the EGFR binding domain suffered conformational changes upon UV illumination. The irradiance used is in the same order of magnitude as the integrated intensity in the solar UVB range. The new photonic technology disables a key receptor and is most likely applicable to the treatment of various types of cancer, alone or in combination with other therapies.

Indexed as

Ultraviolet RaysUltraviolet TherapyErbB ReceptorsHumansProtein BindingProtein ConformationSignal TransductionErbB Receptors

Identifiers

PMID25386651
PMCPMC4227675
OpenAlexW1999767204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.